NCT06012383View on ClinicalTrials.gov

Alvocade® (Bortezomib) Safety and Effectiveness Study

CompletedOBSERVATIONAL
Enrollment

57

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions
Multiple Myeloma, Refractory
Interventions
DRUG

Bortezomib

Alvocade® was given with a dose of 1.3 mg/m2.

All Listed Sponsors
lead

NanoAlvand

INDUSTRY

NCT06012383 - Alvocade® (Bortezomib) Safety and Effectiveness Study | Biotech Hunter | Biotech Hunter